Olema Oncology

74 articles about Olema Oncology

• Olema Oncology to Present New Palazestrant Clinical Data in Combination with CDK4/6 Inhibitors at the 2023 San Antonio Breast Cancer Symposium (SABCS)

  11/28/2023

  Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA) today announced that it will be presenting new Phase 1b/2 clinical data of palazestrant (OP-1250) in combination with CDK4/6 inhibitor ribociclib, a Poster Spotlight Session on Phase 2 clinical data of palazestrant in combination with palbociclib, and a trial-in-progress poster for the OPERA-01 monotherapy Phase 3 pivotal trial at the upcoming San Antonio Breast Cancer Symposium.

• Olema Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update

  11/7/2023

  Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA) today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.

• Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - November 02, 2023

  11/2/2023

  Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, announced that the Company granted stock options to two new employees to purchase an aggregate of 85,000 shares of the Company's common stock, effective as of November 1, 2023.

• Olema Oncology to Participate in Upcoming Investor Conferences in November - November 01, 2023

  11/1/2023

  Olema Pharmaceuticals, Inc. announced that the Company will present at the following upcoming investor conferences in November.

• Olema Oncology Announces Positive Phase 2 Monotherapy Clinical Study Results for Palazestrant

  10/22/2023

  Olema Pharmaceuticals, Inc. announced results from a Phase 2 clinical study of palazestrant, the Company’s complete estrogen receptor antagonist and selective ER degrader, for the treatment of metastatic ER+/HER2- breast cancer.

• Olema Oncology Appoints Oncology Biotech Executive Scott Garland to Board of Directors

  10/17/2023

  Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, announced the appointment of Scott Garland to the company’s Board of Directors.

• Olema Oncology Announces Phase 2 Monotherapy Clinical Results to be Presented at the 2023 ESMO Congress

  10/16/2023

  Olema Pharmaceuticals, Inc. today announced an oral presentation on the Phase 2 monotherapy study results of palazestrant (OP-1250), the Company’s complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD) for the treatment of metastatic breast cancer, at the upcoming European Society for Medical Oncology (ESMO) Congress 2023 in Madrid, Spain, on October 22, 2023.

• Olema Oncology KAT6 Inhibitor Compounds Demonstrate Potent Anti-Tumor Activity

  10/12/2023

  Olema Pharmaceuticals, Inc. today announced new preclinical data regarding the discovery of novel compounds targeting KAT6, an epigenetic target that is dysregulated in breast and other cancers.

• Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 03, 2023

  10/3/2023

  Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, announced that the Company granted stock options to one new employee to purchase an aggregate of 30,000 shares of the Company's common stock, effective as of October 2, 2023.

• Olema Oncology Announces New Preclinical KAT6 Inhibitor Data to be Presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

  9/20/2023

  Olema Pharmaceuticals, Inc. ( “Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced a poster presentation on new discovery compounds targeting KAT6, an epigenetic target that is dysregulated in breast and other cancers.

• Olema Oncology to Participate in Upcoming September 2023 Investor Conferences

  9/6/2023

  Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, announced that the Company will present at the following upcoming investor conferences in September.

• Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 05, 2023

  9/5/2023

  Olema Pharmaceuticals, Inc. announced that the Company granted stock options to one new employee to purchase an aggregate of 61,000 shares of the Company's common stock, effective as of September 1, 2023.

• Olema Oncology Announces Combined Financing for Up to $180 Million

  9/5/2023

  Olema announced today that it has entered into a stock purchase agreement for a private placement of approximately $130 million of common stock.

• Olema Oncology Reports Second Quarter 2023 Financial Results and Provides Corporate Update

  8/8/2023

  Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today reported financial results for the second quarter ended June 30, 2023, and provided a corporate update.

• Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - August 02, 2023

  8/2/2023

  Olema Pharmaceuticals, Inc. announced that the Company granted stock options to two new employees to purchase an aggregate of 29,100 shares of the Company's common stock, effective as of August 1, 2023.

• Olema Oncology to Present at the Canaccord Genuity 43rd Annual Growth Conference

  8/1/2023

  Olema Pharmaceuticals, Inc. announced that Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will participate in a Fireside Chat at the Canaccord Genuity 43rd Annual Growth Conference in Boston on Wednesday, August 9, 2023, at 2:00 p.m. ET.

• Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  7/5/2023

  Olema Pharmaceuticals, Inc. today announced that the Company granted stock options to three new employees to purchase an aggregate of 32,300 shares of the Company's common stock, effective as of July 3, 2023.

• Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 02, 2023

  6/2/2023

  Olema Pharmaceuticals, Inc. announced that the Company granted stock options to two new employees to purchase an aggregate of 17,400 shares of the Company's common stock, effective as of June 1, 2023.

• Olema Oncology to Present at the 2023 Jefferies Healthcare Conference

  5/30/2023

  Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA) today announced that Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will participate in a Fireside Chat at the 2023 Jefferies Healthcare Conference in New York on Wednesday, June 7, 2023, at 3:00 p.m. ET.

• Olema Oncology Announces OP-1250 Continues to Demonstrate Attractive Combinability with CDK4/6 Inhibitor Palbociclib in Phase 1b/2 Study

  5/11/2023

  Olema Pharmaceuticals, Inc. today announced interim results from an ongoing Phase 1b/2 clinical study of OP-1250, the Company’s complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD), in combination with palbociclib, a CDK4/6 inhibitor, for the treatment of ER+/HER2- metastatic breast cancer.